Skip to main content

Table 1 Baseline characteristics of study participants treated with whole-body vibration and teriparatide compared to teriparatide alone

From: The combined effect of parathyroid hormone (1–34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial

  WBV + teriparatide group (n = 17) teriparatide group (n = 18) P value
Age (years) (mean ± SD) 69 ± 5 69 ± 8 0.909
BMI (kg/m2)(mean ± SD) 24.5 ± 4.1 24.1 ± 4.3 0.797
Charlson comorbidity score, median (IQR)
 Smoking, n (%) 1 (0–1) 0 (0–0) 0.087
 Current 4 (24) 4 (22) 0.630
 Former 6 (35) 9 (50)  
 Never 7 (41) 5 (28)  
Physical activity at baseline*, n (%)
 Low 10 (59) 8 (39) 0.421
 moderate 4 (23) 8 (50)  
 High 3 (18) 2 (11)  
Falls in the last 12 months¤, n (%)
 None 10 (59) 11 (61) 0.244
 1 3 (18) 6 (33)  
  ≥ 2 4 (24) 1 (6)  
Alcohol, (units a day)¤, n (%)
 none 3 (18) 6 (33) 0.543
 up to 1 11 (64) 10 (56)  
  > 1 3 (18) 2 (11)  
Ability to rise from chair without using arms ¤, n (%) 12 (71) 16 (89) 0.177
  1. P values for difference t-test when normal distribution, chi squared for categorical, mann-whitney test for continual non-normal distribution.* Estimated using the IPAQ questionnaire, self-reported outcome. ¤ Self-reported outcome BMI body mass index, WBV whole-body vibration